AG-181
Phase 1Small molecule
AG-181 is one of 7 small molecule programs targeting Phenylketonuria. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Phenylketonuria
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
L-Carnitine
IIperboreal Pharma Srl
Phase 3
CEB-01
BioMarin PharmaceuticalPhase 3
Sephience
PPTC Therapeutics
Phase 3
Pegvaliase
BioMarin PharmaceuticalPreclinical
AG-181
AAgios Pharmaceuticals, Inc.
Phase 1
Repinatrabit
OtsukaPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AG-181. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAgios Pharmaceuticals, Inc.